The largest database of trusted experimental protocols
> Chemicals & Drugs > Amino Acid > Lipoprotein cholesterol

Lipoprotein cholesterol

Lipoprotein cholesterol refers to the cholesterol contained within lipoprotein particles, which are macromolecular complexes that transport lipids in the blood.
These lipoproteins include low-density lipoproteins (LDL), high-density lipoproteins (HDL), and other classes.
Measuring and analyzing lipoprotein cholesterol levels is crucial for assessing cardiovascular health and risk.
PubCompare.ai's AI-driven platform can help effeciently locate the most reliable protocols from scientific literature, pre-prints, and patents to optimize your lipoprotein cholesterol research, enhancing reproducibility and accuracy.

Most cited protocols related to «Lipoprotein cholesterol»

Do and colleagues16 (link) performed a two-sample MR analysis to evaluate the causal effect of low-density lipoprotein cholesterol (LDL-C), high-density lipoprotein cholesterol (HDL-C) and triglycerides on coronary heart disease (CHD) risk, using a total of 185 genetics variants. Summary association results were obtained from the Global Lipids Genetics Consortium17 (link) and the Coronary Artery Disease Genome-Wide Replication and Meta-Analysis Consortium,18 (link) and were downloaded from Do and colleagues’ supplementary material (standard errors were estimated based on the regression coefficients and P-values). Genetic variants were classified as instruments for each lipid fraction using a statistical criterion (P < 1 × 10−8), resulting in 73 instruments for LDL-C, 85 for HDL-C and 31 for triglycerides.
White and colleagues19 (link) performed a similar analysis, but with plasma urate levels rather than lipid fractions. 31 variants associated with urate levels (P < 5 × 10−7) were used as genetic instruments, and the required summary statistics were obtained from the GWAS catalogue [https://www.ebi.ac.uk/gwas/].
Full text: Click here
Publication 2017
Cholesterol, beta-Lipoprotein Coronary Arteriosclerosis DNA Replication Genetic Diversity Genome Genome-Wide Association Study Heart Disease, Coronary High Density Lipoprotein Cholesterol Lipids Plasma Reproduction Triglycerides Urate
The Metabochip was designed by representatives of the Body Fat Percentage [9] (link), CARDIoGRAM (coronary artery disease and myocardial infarction) [10] (link), DIAGRAM (type 2 diabetes) [11] (link), GIANT (anthropometric traits) [3] (link), [12] (link), [13] (link), Global Lipids Genetics (lipids) [4] (link), HaemGen (hematological measures) [14] (link), ICBP (blood pressure) [15] (link), MAGIC (glucose and insulin) [16] (link)–[18] (link), and QT-IGC (QT interval) [19] (link), [20] (link) GWAS meta-analysis consortia. The array is comprised of SNPs selected across two tiers of traits (Table 1). Tier 1 is comprised of eleven traits deemed to be of primary interest: type 2 diabetes (T2D), fasting glucose, coronary artery disease and myocardial infarction (CAD/MI), low density lipoprotein (LDL) cholesterol, high density lipoprotein (HDL) cholesterol, triglycerides, body mass index (BMI), systolic and diastolic blood pressure, QT interval, and waist-to-hip ratio adjusted for BMI (WHR). Tier 2 is comprised of twelve traits of secondary interest: fasting insulin, 2-hour glucose, glycated hemoglobin (HbA1c), T2D age of diagnosis, early onset T2D (diagnosis age<45 years), waist circumference adjusted for BMI, height, body fat percentage, total cholesterol, platelet count, mean platelet volume, and white blood cell count.
We included three design classes of SNPs on the Metabochip (Table 2):
In total, 217,695 SNPs were chosen for the array (Table 2). 20,970 SNPs (9.6%) failed during the assay manufacturing process, resulting in 196,725 SNPs available for genotyping. A summary file annotating each Metabochip SNP with ascertainment criteria, SNP assay, a list of unintended duplicate SNPs (Supplementary Table S4), and reference strand orientation for alleles is provided at http://www.sph.umich.edu/csg/kang/MetaboChip/.
Full text: Click here
Publication 2012
ADCAD1 Alleles Biological Assay Blood Pressure Body Fat Cholesterol Diabetes Mellitus, Non-Insulin-Dependent Diagnosis Genome-Wide Association Study Gigantism Glucose Hemoglobin, Glycosylated High Density Lipoprotein Cholesterol Index, Body Mass Insulin Leukocyte Count Lipids Low-Density Lipoproteins Platelet Counts, Blood Pressure, Diastolic Single Nucleotide Polymorphism Systole Triglycerides Volumes, Mean Platelet Waist-Hip Ratio Waist Circumference
Data were obtained from the third National Health and Nutrition Examination Survey (NHANES III), a probability sample of the US civilian, noninstitutionalized population that included an oversample of non-Hispanic blacks and Mexican Americans [23 ]. NHANES III, conducted over the period 1988–1994, was unique among large US surveys because it incorporated assays of serum apolipoproteins B and A1 (ApoB, ApoA1; restricted to survey years 1988–1991). The analytic population from the seven-year survey contained 4,447 male and 4,733 female participants who were aged 18+ years, not pregnant, had fasted 8–19 hours before their laboratory examination, and had data available on basic anthropometry and fasting serum TGs (excluding three persons with a TG concentration >15 mmol/L). Participants were asked to complete a household interview and a standardized examination, including measurement of the standing waist circumference (in the horizontal plane at the level just above the right iliac crest, at minimal respiration) [24 ,25 (link)]. Serum TGs were measured enzymatically after hydrolysis to glycerol (Hitachi 704 Analyzer; Boehringer Mannheim, Indianapolis, Indiana); the coefficient of variation was 3–5 percent over the study and across the clinical range. Additional details of all laboratory procedures are available elsewhere [26 ]. Calculations of low-density lipoprotein (LDL) cholesterol concentration were limited to participants with TG concentrations below 4.5 mmol/L (a requirement of the Friedewald equation [27 (link)]) who had fasted at least nine hours.
Sampling weights from NHANES III were used with the software programs SAS, SAS/Graph (Release 8.2, SAS Institute, Cary, NC), and SUDAAN (Release 8.0, Research Triangle Institute, Research Triangle, NC), to estimate the sizes of the represented adult populations, to describe the distributions in the population of risk factors associated with LAP and BMI, and to perform analyses using multivariable linear regression. The analyses thus incorporated sampling weights that accounted for unequal selection probabilities (clustered design, planned oversampling, and differential nonresponse) [28 ]. Based on the sampling weights assigned, the analytic cohort represented an estimated total of 100,048,439 US adults aged 18+ years, 50.5 percent (SE 0.7) of them women, with a distribution of race-ethnicity that was 76.0 (1.5) percent non-Hispanic white, 10.5 (0.6) percent non-Hispanic black, 5.3 (0.5) percent Mexican American, and 8.1 (1.1) percent other.
Sex-specific bubble plots of population density by the values for WC (to the nearest cm) and TG concentration (to the nearest 0.1 mmol/L) were prepared to represent US adults in three age ranges (figure 1). The area of each bubble on these plots is proportional to the estimated number of men or women represented by those intersections. A sex-specific hypothetical minimum value for WC (that is, the waist size that theoretically contained only abdominal muscle, viscera, and vertebral bone) was estimated by calculating the mean minus two standard deviations of the log-transformed WC value among the estimated 15.00 million persons aged 18–24 years. These estimated minimum WC values (65 cm for men and 58 cm for women) were very similar to minimum values reported in a survey of 18 year-old Canadians in 1981 [29 (link)].
The minimum WC values were used to define sex-specific origin points (near the left-lower corner of each panel in figure 1) that represented a hypothetical state in which TG concentrations were arbitrarily set to zero and the waist size (greater for men than women) comprised primarily lean truncal tissue. A comparison of sex-specific bubble plots by age group confirmed that increasing age was accompanied by a shift of the population density upward (increasing waist size) and to the right (increasing circulating TG). Consistent with this empirical observation, the LAP was defined to describe the extent to which an individual had travelled the route – in theory – of both increasing waist and increasing TG:
LAP for men = (WC [cm] - 65) × (TG concentration [mmol/L])
LAP for women = (WC [cm] - 58) × (TG concentration [mmol/L])
In order to avoid having nonpositive values for LAP, any waist values for men that were 65 cm or less (five men in the NHANES III sample, all aged 18–22 years) were revised upward to 66.0 cm. No women in the entire NHANES III sample had a waist circumference less than 58.4 cm.
Full text: Click here
Publication 2005
One-third of patients in the study sample were randomly assigned to a validation data set. Patients were grouped by those fulfilling the Friedewald equation criterion of triglycerides lower than 400 mg/dL (to convert to millimoles per liter, multiply by 0.0113) and those with triglycerides of 400 or higher.
Friedewald LDL-C (LDL-CF) was estimated as (non–HDL-C) – (triglycerides/5) in mg/dL.1 (link) Novel LDL-C (LDL-CN) estimates were derived as (non–HDL-C) – (triglycerides/adjustable factor mg/dL), where the adjustable factor was determined as the strata-specific median TG:VLDL-C ratio. Numerical subscripts (eg, LDL-C180 for 180-cell stratification) were used to identify variants of LDL-CN. Alternative LDL-C estimates were also calculated based on previously proposed formulas.2 (link),18 (link)–23 (link) The reference standard direct LDL-C (LDL-CD) was subtracted from each LDL-C estimate to determine the absolute difference in their values in milligrams per deciliter.
Direct and estimated LDL-C values were classified according to clinical practice guidelines in the United States (<70, 70–99, 100–129, 130–159, 160–189, and ≥190 mg/dL; to convert to millimole per liter, multiply by 0.0259) and Europe (<70, 70–99, 100–154, 155–189, and ≥190 mg/dL).3 (link)–5 (link),7 (link),8 (link) Concordance in classification between LDL-C estimates and LDL-CD was examined in the whole study population and subgroups. The initial classification was defined by the estimated parameter because this is the parameter routinely available in clinical practice. Odds ratios (ORs) for discordance in subgroups were calculated using logistic regression. Based on prior literature,24 (link)–30 (link) definitions of Fredrickson-Levy phenotypes are provided in eTable 4 in the Supplement.
Statistical analyses were performed in Stata (StataCorp), version 11.0, and logarithmically scaled pseudocolor encoded data density plots were generated in R (http://r-project.org), version 2.14.1. We considered a 2-tailed P of less than .05 statistically significant.
Publication 2013
Cells Diet, Formula Dietary Supplements Patients Phenotype Triglycerides
Cholesterol efflux capacity was quantified in blood samples from the cohort of healthy volunteers as described previously.17 (link) This assay quantifies total efflux mediated by pathways of known relevance in cholesterol efflux from macrophages (i.e., ATP-binding cassette transporter A1 [ABCA1] and G1 [ABCG1], scavenger receptor B1, and aqueous diffusion).17 (link) Each sample was run in triplicate, with a mean coefficient of variation of 4.3%. Values were normalized by dividing the efflux capacity of individual patients by the efflux capacity of a serum pool run with each assay.
Cholesterol efflux capacity in the coronary disease and pharmacologic-study cohorts was quantified with the use of a slightly modified method designed to increase throughput. J774 cells, derived from a murine macrophage cell line, were plated and radiolabeled with 2 μCi of 3H-cholesterol per milliliter. ABCA1 was up-regulated by means of a 6-hour incubation with 0.3 mM 8-(4-chlorophenylthio)-cyclic AMP. Subsequently, efflux mediums containing 2.8% apolipoprotein B–depleted serum were added for 4 hours. All steps were performed in the presence of the acyl–coenzyme A:cholesterol acyltransferase inhibitor CP113,818 (2 μg per milliliter). In a pilot study involving serum samples from 20 healthy volunteers, results from the original assay procedure17 (link) and the modified method were strongly correlated (r = 0.85).
Liquid scintillation counting was used to quantify the efflux of radioactive cholesterol from the cells. The quantity of radioactive cholesterol incorporated into cellular lipids was calculated by means of isopropanol extraction of control wells not exposed to patient serum. Percent efflux was calculated by the following formula: [(microcuries of 3H-cholesterol in mediums containing 2.8% apolipoprotein B–depleted serum – microcuries of 3H-cholesterol in serum-free mediums) ÷ microcuries of 3H-cholesterol in cells extracted before the efflux step] × 100. All assays were performed in duplicate. To correct for interassay variation across plates, a pooled serum control from five healthy volunteers was included on each plate, and values for serum samples from patients were normalized to this pooled value in subsequent analyses. Additional studies that were performed to validate the measurement of cholesterol efflux capacity are described in the Supplementary Appendix.
Publication 2011
ABCA1 protein, human ABCG1 protein, human Acyl Coenzyme A Apolipoproteins B Biological Assay BLOOD Cell Lines Cells Cholesterol Culture Media Cyclic AMP Diffusion Healthy Volunteers Heart Disease, Coronary Isopropyl Alcohol Lipids Macrophage Mus Patients Radioactivity Scavenger Receptor Serum Sterol O-Acyltransferase

Most recents protocols related to «Lipoprotein cholesterol»

Serum was obtained from patients with SLE after a 12-hour fast in the morning. Processed serum was stored at −80°C until retrieval for analyses. Analyses were performed for total cholesterol, triglycerides, HDL by automated clinical chemistry analyzer (AU5800, Beckman Coulter, Florida) in NUH, a College of American Pathologists accredited laboratory. LDL was calculated using the Friedewald formula. LDL and HDL subfractions were analysed using Lipoprint LDL System (which resolves up to 12 lipoprotein subfractions: very LDL (1), mid-band (3), LDL (7) and HDL (1); Lipoprint, Quantimetrix Corporation, California) and Lipoprint HDL System (which separates HDL into 10 subfractions; Lipoprint, Quantimetrix Corporation, California), respectively. Mid-bands comprise mainly of intermediate-density lipoproteins. HDL 1–3, 4–7 and 8–10 are classified as large, intermediate and small subfractions by the Lipoprint HDL System, respectively. The relative area (%) for each lipoprotein band is determined and multiplied by the total cholesterol concentration of the sample to yield the amount of cholesterol for each band (mg/dL).
Publication 2024
The TG/HDL-C ratio was considered a continuous variable and calculated as follows: TG/HDL-C ratio = triglycerides divided by high-density lipoprotein cholesterol.
Full text: Click here
Publication 2024
Plasma of 14-week-old mice were used to measure total cholesterol in plasma lipoprotein fractions. Lipoproteins were separated from plasma by size exclusion chromatography fast protein LC (FPLC) using a Superose 6 column on an FPLC system with a Model 500 pump from Waters (Milford, MA). In short, and as described in a previous study83 (link), a 100 μL aliquot of mouse plasma pooled equally from four different mice per group was injected into a 1.0-ml sample loop and separated with a buffer (0.15 M NaCl, 0.01 M Na2HPO4, and 0.1 mM EDTA) at a flow rate of 0.5 mL/min. Sixty fractions of 300 µL were collected, each containing its correspondent lipoproteins. Batch analysis was performed to measure circulating total cholesterol (Fujifilm Medical Systems U.S.A., Inc. cat. 999-02601) in plasma lipoprotein fractions according to the manufacturer’s protocol.
Full text: Click here
Publication 2024

Protocol full text hidden due to copyright restrictions

Open the protocol to access the free full text link

Publication 2024

Protocol full text hidden due to copyright restrictions

Open the protocol to access the free full text link

Publication 2024

Top products related to «Lipoprotein cholesterol»

Sourced in United States, Japan, Germany, United Kingdom, China, Italy, Canada
The AU5800 is a chemistry analyzer designed for high-throughput clinical laboratory testing. It features advanced optics and automation to provide reliable and efficient sample processing. The core function of the AU5800 is to perform a variety of clinical chemistry tests, including immunoassays, on patient samples.
Sourced in Switzerland, Germany, United States, Japan, France, Italy, China, United Kingdom, Sweden
The Cobas 8000 is a modular, automated in-vitro diagnostic system designed for high-throughput clinical chemistry and immunochemistry testing. It is used to perform a wide range of laboratory tests, including those for chemistry, immunoassay, and electrolyte analysis. The Cobas 8000 is capable of processing a large volume of samples efficiently and accurately.
Sourced in Switzerland, Germany, United States, Japan, Denmark, Italy, France, United Kingdom, Belgium, Norway, China, Israel, Poland, Netherlands, Sweden
The Cobas 6000 is an automated clinical chemistry and immunoassay analyzer system designed for high-volume laboratory testing. It combines the features of two separate instruments, the Cobas c 501 module for clinical chemistry and the Cobas e 601 module for immunoassays, into a single integrated platform. The Cobas 6000 system is capable of performing a wide range of diagnostic tests, including biochemical, immunological, and specialty assays.
Sourced in Japan, United States, Germany, Finland
The Hitachi Automatic Analyzer 7600 is a versatile laboratory instrument designed for the automated analysis of various samples. It is capable of performing a wide range of clinical chemistry tests, including quantitative determination of analytes in biological fluids.
Sourced in Germany, United States, United Kingdom, Japan, Denmark
The ADVIA 1800 is a clinical chemistry analyzer designed for use in medical laboratories. It is capable of performing a wide range of common clinical chemistry tests on patient samples. The ADVIA 1800 automates the analysis process, providing efficient and accurate results to support patient diagnosis and treatment.
Sourced in United States, Germany, United Kingdom
The Variant II is a laboratory equipment designed for protein analysis. It utilizes electrophoresis technology to separate and analyze proteins based on their molecular weight and charge. The core function of the Variant II is to provide consistent and reliable protein separation for various applications in the life sciences and biotechnology industries.
Sourced in Germany, United States, China, United Kingdom, Japan, Italy, Spain
The ADVIA 2400 is a fully automated clinical chemistry analyzer designed for high-volume laboratory testing. It features advanced technology for efficient sample processing and accurate analysis of a wide range of clinical chemistry parameters.
Sourced in Japan, Germany, United States, France, China
The AU2700 is a fully automated clinical chemistry analyzer designed for high-throughput laboratory testing. It offers a wide range of analytical capabilities, including photometric, ion-selective, and enzymatic assays. The AU2700 is capable of performing a variety of clinical chemistry tests, such as those for metabolic, renal, and liver function.
Sourced in Switzerland, Germany, United States, Australia, China, United Kingdom, Philippines
The Cobas Integra 400 Plus is a clinical chemistry analyzer designed for in-vitro diagnostics. It is capable of performing a variety of tests on biological samples to aid in the diagnosis and monitoring of medical conditions. The core function of the Cobas Integra 400 Plus is to analyze samples and provide quantitative results for clinical parameters.
Sourced in Switzerland, Germany, United States, Japan
The Cobas Integra 800 is a fully automated, high-throughput clinical chemistry analyzer designed for use in medical laboratories. It is capable of performing a wide range of clinical chemistry tests on a variety of sample types. The Cobas Integra 800 utilizes advanced technology to provide accurate and reliable results, with the ability to handle a high volume of samples efficiently.

More about "Lipoprotein cholesterol"